Get the Stockscreener App
1.76
4.86%
-0.09
Can-Fite Biopharma Ltd ADR stock is traded at $1.76, with a volume of 26,978.
It is down -4.86% in the last 24 hours and down -21.43% over the past month.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
See More
Previous Close:
$1.85
Open:
$1.92
24h Volume:
26,978
Relative Volume:
0.85
Market Cap:
$3.77M
Revenue:
$407.80K
Net Income/Loss:
$-9.90M
P/E Ratio:
-0.1414
EPS:
-12.4498
Net Cash Flow:
$-9.00M
1W Performance:
-7.37%
1M Performance:
-21.43%
6M Performance:
-42.86%
1Y Performance:
-83.70%
1-Day Range:
$1.75
$1.92
1-Week Range:
$1.75
$2.02
52-Week Range:
$1.75
$12.30
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Name
Can-Fite Biopharma Ltd ADR
Sector
Industry
Phone
972 3 924 1114
Address
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Compare CANF vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
1.76 | 3.77M | 407.80K | -9.90M | -9.00M | -12.45 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-13-26 | Upgrade | D. Boral Capital | Hold → Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| Oct-19-16 | Resumed | ROTH Capital | Buy |
| Aug-29-16 | Resumed | Rodman & Renshaw | Buy |
| Nov-30-15 | Reiterated | H.C. Wainwright | Buy |
| Mar-31-15 | Reiterated | H.C. Wainwright | Buy |
| Mar-30-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-29-14 | Reiterated | ROTH Capital | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
View All
Can-Fite Biopharma Ltd ADR Stock (CANF) Latest News
With financing closed, Scinai (SCNI) estimates runway to late 2027, subject to sales, collections and execution. - Stock Titan
Each depositary share represents 10,000 ordinary shares at RedHill Biopharma (RDHL). - Stock Titan
Nasdaq gives RedHill Biopharma (NASDAQ: RDHL) more time to clear its $1 bid-price hurdle - Stock Titan
If all warrants are exercised for cash, Can-Fite (CANF) could receive $8.31M as it registers shares for resale. - Stock Titan
Warrants on 7.6M CANF shares highlight dilution risk - Stock Titan
CANFCan-Fite Biopharma Ltd ADR Short Interest - Finviz
Repriced deal gives Can-Fite (CANF) $4M cash and 3.18M new ADS warrants - Stock Titan
CANF 6-K & SEC Filings - Yahoo Finance Australia
Which stocks are gapping on Wednesday? - ChartMill
Discover the top movers in Wednesday's pre-market session. - ChartMill
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - globenewswire.com
Can-Fite BioPharma (CANF) halves warrant price in cash-for-warrants deal - Stock Titan
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - markets.businessinsider.com
Can-Fite (CANF) Quarterly Figures: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Share Response: The Stock Records a 0.60% Decrease on the DayFinal Results - careplusvn.com
Can-Fite (CANF) Quarterly Figures: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Share Response: The Stock Records a 0.60% Decrease on the DayShort-Term Outlook - dars.gov.et
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionALMA Signal - careplusvn.com
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionETF Liquidity - dars.gov.et
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionDouble Bottom - siam.in
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionZero Lag EMA - www.dars.gov.et
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionFear Greed Index - dars.gov.et
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionMACD Signal Stocks - www.dars.gov.et
Can-Fite (CANF) Range: Loses 0.29% to Close at $3.44 for the Current Session; Next Test: $3.27 and $3.61 Define the Nearby Reference Levels in the Current UpdateGap and Reverse - careplusvn.com
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates - Sahm
Baidu, Inc. (BIDU) CEO logs 852,904 restricted share conversions and major Class B stake - Stock Titan
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology - GlobeNewswire Inc.
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Hesai Group (NYSE: HSAI) enacts 1-for-8 share subdivision and updates ADS ratio - Stock Titan
Why is Can-Fite BioPharma stock climbing today? - Investing.com
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients - Sahm
H.C. Wainwright raises Can-Fite BioPharma price target to $8 on trial data - Investing.com
On Wednesday, there are stocks with unusual volume. Let's take a look. - ChartMill
Wednesday's session: gap up and gap down stocks - ChartMill
Can Fite Biopharma stock surges 65% on pancreatic cancer data By Investing.com - Investing.com Nigeria
Can Fite Biopharma stock surges 65% on pancreatic cancer data - Investing.com
What's going on in today's pre-market session - ChartMill
Can-Fite BioPharma Ltd. Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Can-Fite BioPharma Ltd. Sponsored ADR Actuals & Estimates (AMEX:CANF) - TradingView
Friday's after hours session: top gainers and losers - ChartMill
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Can Fite Biopharma stock jumps on Japan patent for obesity drug - Investing.com South Africa
Can-Fite BioPharma (NYSEAMERICAN:CANF) jumps after Japan patent update - TechStock²
Top movers in Friday's pre-market session - ChartMill
Can-Fite BioPharma Ltd. Sponsored ADR Actuals & Estimates (AMEX:CANF) - TradingView
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson - Sahm
Form 6K Can-Fite BioPharma Ltd. For: 22 June By Investing.com - Investing.com South Africa
Form 6K Can-Fite BioPharma Ltd. For: 22 June By Investing.com - Investing.com Canada
RedHill closes $6M financing, with up to $13.4M more possible - Stock Titan
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 - Sahm
CANF Stock Price, Quote & Chart - ChartMill
Can-Fite Biopharma Ltd ADR Stock (CANF) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):